An Unbiased View of CFSE
A stage I examine in Japanese patients with R/R NHL, which include ATLL sufferers, confirmed a manageable security profile, and 40 mg two times every week was chosen for subsequent clinical progress.The intention of the current period IIb review was to evaluate the efficacy and security of tucidinostat in sufferers with R/R ATLL. This can be the